Mitochondria-targeted triphenylphosphonium-based compounds do not affect estrogen receptor α.

Estrogen Targeting mitochondria Triphenylphosphonium

Journal

PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425

Informations de publication

Date de publication:
2020
Historique:
received: 08 11 2019
accepted: 25 02 2020
entrez: 8 4 2020
pubmed: 8 4 2020
medline: 8 4 2020
Statut: epublish

Résumé

Targeting negatively charged mitochondria is often achieved using triphenylphosphonium (TPP) cations. These cationic vehicles may possess biological activity, and a docking study indicates that TPP-moieties may act as modulators of signaling through the estrogen receptor α (ERα). Moreover, in vivo and in vitro experiments revealed the estrogen-like effects of TPP-based compounds. Here, we tested the hypothesis that TPP-based compounds regulate the activity of ERα. We used ERa-positive and ERα-negative human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231, respectively). Cell proliferation was measured using a resazurin cell growth assay and a real-time cell analyzer assay. Cell cycle progression was analyzed using flow cytometry. Real-time PCR was used to assess mRNA expression of endogenous estrogen-responsive genes. Luciferase activity was measured to evaluate transcription driven by estrogen-responsive promoters in cells transfected with an estrogen response element (ERE) The TPP-based molecules SkQ1 and C TPP-based compounds do not possess properties typical of ERα agonists.

Sections du résumé

BACKGROUND BACKGROUND
Targeting negatively charged mitochondria is often achieved using triphenylphosphonium (TPP) cations. These cationic vehicles may possess biological activity, and a docking study indicates that TPP-moieties may act as modulators of signaling through the estrogen receptor α (ERα). Moreover, in vivo and in vitro experiments revealed the estrogen-like effects of TPP-based compounds. Here, we tested the hypothesis that TPP-based compounds regulate the activity of ERα.
METHODS METHODS
We used ERa-positive and ERα-negative human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231, respectively). Cell proliferation was measured using a resazurin cell growth assay and a real-time cell analyzer assay. Cell cycle progression was analyzed using flow cytometry. Real-time PCR was used to assess mRNA expression of endogenous estrogen-responsive genes. Luciferase activity was measured to evaluate transcription driven by estrogen-responsive promoters in cells transfected with an estrogen response element (ERE)
RESULTS RESULTS
The TPP-based molecules SkQ1 and C
CONCLUSION CONCLUSIONS
TPP-based compounds do not possess properties typical of ERα agonists.

Identifiants

pubmed: 32257641
doi: 10.7717/peerj.8803
pii: 8803
pmc: PMC7102506
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e8803

Informations de copyright

©2020 Zinovkina et al.

Déclaration de conflit d'intérêts

The authors declare there are no competing interests.

Références

Eur J Cell Biol. 2017 May;96(3):254-265
pubmed: 28325500
Curr Genomics. 2006;7(8):497-508
pubmed: 18369406
Endocr Relat Cancer. 2003 Mar;10(1):23-42
pubmed: 12653669
Curr Mol Pharmacol. 2019;12(3):202-214
pubmed: 30479224
Bioinformation. 2009;3(7):303-7
pubmed: 19293997
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):89-96
pubmed: 17113977
Biochemistry (Mosc). 2014 Feb;79(2):124-30
pubmed: 24794727
Reprod Med Biol. 2016 Dec 05;16(1):4-20
pubmed: 29259445
Blood. 2003 Oct 1;102(7):2653-9
pubmed: 12791649
Biochemistry (Mosc). 2014 Oct;79(10):1136-9
pubmed: 25519073
Cell Immunol. 2015 Apr;294(2):63-9
pubmed: 25682174
Biochemistry (Mosc). 2012 Dec;77(12):1382-6
pubmed: 23244734
Biol Proced Online. 2009 Dec 03;11:227-40
pubmed: 19957063
Biochemistry (Mosc). 2008 Dec;73(12):1329-42
pubmed: 19120018
Chem Rev. 2017 Aug 9;117(15):10043-10120
pubmed: 28654243
Mol Biol Cell. 2006 May;17(5):2125-37
pubmed: 16495339
Horm Cancer. 2013 Aug;4(4):222-32
pubmed: 23526455
Molecules. 2015 Aug 11;20(8):14487-503
pubmed: 26270657
J Biol Chem. 2011 May 20;286(20):17831-40
pubmed: 21454507
Aging (Albany NY). 2014 Aug;6(8):661-74
pubmed: 25239871
Endocrinology. 1999 Dec;140(12):5566-78
pubmed: 10579320
J Cell Biochem. 2016 Nov;117(11):2521-32
pubmed: 26990649
Curr Aging Sci. 2017;10(1):41-48
pubmed: 27659264
Free Radic Biol Med. 2010 Jan 1;48(1):161-72
pubmed: 19854266
Am J Transl Res. 2018 Jun 15;10(6):1887-1899
pubmed: 30018728
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):663-8
pubmed: 20080732
Cells. 2015 Aug 21;4(3):427-51
pubmed: 26308058
Oxid Med Cell Longev. 2016;2016:8703645
pubmed: 27293517
Curr Neuropharmacol. 2016;14(6):641-53
pubmed: 26955967

Auteurs

Ludmila A Zinovkina (LA)

Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Institute of Mitoengineering, Moscow State University, Moscow, Russia.

Alina K Galivondzhyan (AK)

Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.

Anastasia S Prikhodko (AS)

Institute of Mitoengineering, Moscow State University, Moscow, Russia.
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.

Ivan I Galkin (II)

Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.

Roman A Zinovkin (RA)

Institute of Mitoengineering, Moscow State University, Moscow, Russia.
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia.

Classifications MeSH